Penn Capital Management Company LLC Invests $448,000 in ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Penn Capital Management Company LLC invested approximately $448,000 in ANI Pharmaceuticals, acquiring 6,696 shares during the first quarter.
• ANI Pharmaceuticals reported a quarterly revenue of $211.37 million, significantly beating analysts' expectations of $187.18 million, and posted an EPS of $1.80.
• Insider trading activity revealed COO Muthusamy Shanmugam sold 52,990 shares for approximately $4.6 million, representing a 9.06% decrease in his stake.

Penn Capital Management Company LLC bought a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 6,696 shares of the specialty pharmaceutical company's stock, valued at approximately $448,000.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Hohimer Wealth Management LLC increased its position in shares of ANI Pharmaceuticals by 5.2% during the first quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock worth $334,000 after acquiring an additional 247 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in ANI Pharmaceuticals by 3.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock worth $582,000 after purchasing an additional 364 shares in the last quarter. MetLife Investment Management LLC grew its stake in ANI Pharmaceuticals by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 11,397 shares of the specialty pharmaceutical company's stock worth $630,000 after purchasing an additional 675 shares in the last quarter. GAMMA Investing LLC grew its stake in ANI Pharmaceuticals by 163.8% in the first quarter. GAMMA Investing LLC now owns 1,419 shares of the specialty pharmaceutical company's stock worth $95,000 after purchasing an additional 881 shares in the last quarter. Finally, National Bank of Canada FI acquired a new position in ANI Pharmaceuticals in the first quarter worth about $79,000. 76.05% of the stock is owned by hedge funds and other institutional investors.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $91.01 on Friday. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The business has a 50 day moving average of $70.63 and a two-hundred day moving average of $65.95. ANI Pharmaceuticals, Inc. has a 52 week low of $52.50 and a 52 week high of $92.53. The company has a market cap of $1.97 billion, a P/E ratio of -118.19 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The company had revenue of $211.37 million during the quarter, compared to the consensus estimate of $187.18 million. During the same period in the previous year, the firm posted $1.02 earnings per share. ANI Pharmaceuticals's quarterly revenue was up 53.2% compared to the same quarter last year. As a group, analysts anticipate that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently commented on ANIP. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday. HC Wainwright reiterated a "buy" rating and issued a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday, August 11th. Piper Sandler reiterated an "overweight" rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $84.75.

Insider Buying and Selling

In other ANI Pharmaceuticals news, COO Muthusamy Shanmugam sold 52,990 shares of ANI Pharmaceuticals stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $87.15, for a total value of $4,618,078.50. Following the completion of the transaction, the chief operating officer directly owned 531,920 shares in the company, valued at $46,356,828. The trade was a 9.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Stephen P. Carey sold 50,000 shares of the business's stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $86.07, for a total value of $4,303,500.00. Following the transaction, the chief financial officer owned 180,863 shares of the company's stock, valued at approximately $15,566,878.41. This represents a 21.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 401,247 shares of company stock valued at $35,300,435 over the last 90 days. 11.10% of the stock is owned by corporate insiders.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.